Lihong Liu

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

This paper evaluates the antigenicity and receptor affinity of the SARS-CoV-2 BA.2.86 subvariant, finding it not more resistant to human sera than other variants but with specific mAb resistance and high receptor affinity.